() said a listing on the US tech market NASDAQ is very much an option as it brought on board an American investment bank.
Health Partners will advise on its future financing options within the US market, investors were told.
Chief executive Graham Lumsden told Proactive: “One of the differences between the London markets and the US is that there are a large number of specialist pharma-biotech investors in the US.”
What is helping the firm to do, he said, is understand “how we identify the right investors in the US, what our story needs to be, and how we communicate with these people.”
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE